Jubilant Pharmova Ltd. has posted a consolidated net profit of ₹151.3 crore for the fourth quarter ended March 31, 2025, signaling a strong turnaround from the ₹61.8 crore loss recorded in the same period last year.
The company’s total revenue from operations rose to ₹1,928.8 crore, compared to ₹1,758.6 crore in the corresponding quarter of the previous fiscal. However, total expenses also increased, reaching ₹1,731.3 crore, up from ₹1,661.2 crore a year ago.
For the full fiscal year FY25, Jubilant Pharmova reported a net profit of ₹836.3 crore, a significant rise from ₹72.7 crore in FY24. The company’s annual revenue also saw an uptick, reaching ₹7,234.5 crore, compared to ₹6,702.9 crore in the preceding year.
In light of its improved financial performance, the board of directors has recommended a final dividend of ₹5 per equity share, subject to shareholder approval.
The company’s recovery underscores its resilience and strategic growth initiatives, reinforcing its position in the pharmaceutical sector.
